Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Revolution Medicines (RVMD) Amortization of Deferred Charges (2020 - 2025)

Historic Amortization of Deferred Charges for Revolution Medicines (RVMD) over the last 3 years, with Q3 2025 value amounting to $11.4 million.

  • Revolution Medicines' Amortization of Deferred Charges changed N/A to $11.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $13.1 million, marking a year-over-year increase of 43680.33%. This contributed to the annual value of $3.2 million for FY2021, which is 1095.6% up from last year.
  • Per Revolution Medicines' latest filing, its Amortization of Deferred Charges stood at $11.4 million for Q3 2025.
  • In the past 5 years, Revolution Medicines' Amortization of Deferred Charges ranged from a high of $11.4 million in Q3 2025 and a low of $691000.0 during Q3 2021